EXEMESTANE
ER+ Breast Cancer
National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 66/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the ER+ Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib Forward Pharmaceuticals Co., Ltd. | Phase 3 | BB |
Gdc-0068 Royal Marsden NHS Foundation Trust | Phase 2 | BB |
Entinostat Syndax Pharmaceuticals | Phase 2 | B |
Duloxetine European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | B |
FUROSEMIDE European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | B |
View all 19 →
Same molecule, other indications
EXEMESTANE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →